Literature DB >> 26874565

ST-segment abnormalities are associated with long-term prognosis in non-ST-segment elevation acute coronary syndromes: The ERICO-ECG study.

Rodrigo M Brandão1, Nelson Samesima2, Carlos A Pastore2, Henrique L Staniak1, Paulo A Lotufo3, Isabela M Bensenor3, Alessandra C Goulart1, Itamar S Santos4.   

Abstract

INTRODUCTION: We aimed to identify whether ST-segment abnormalities, in the admission or during in-hospital stay, are associated with survival and/or new incident myocardial infarction (MI) in 623 non-ST-elevation acute coronary syndrome participants of the Strategy of Registry of Acute Coronary Syndrome (ERICO) study.
MATERIALS AND METHODS: ERICO is conducted in a community-based hospital. ST-segment analysis was based on the Minnesota Code. We built Cox regression models to study whether ECG was an independent predictor for clinical outcomes.
RESULTS: Median follow-up was 3years. We found higher risk of death due to MI in individuals with ST-segment abnormalities in the final ECG (adjusted hazard ratio: 2.68; 95% confidence interval: 1.14-6.28). Individuals with ST-segment abnormalities in any tracing had a non-significant trend toward a higher risk of fatal or new non-fatal MI (p=0.088).
CONCLUSIONS: ST-segment abnormalities after the initial tracing added long-term prognostic information.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cohort; Coronary heart disease; Electrocardiography; Prognosis

Mesh:

Year:  2016        PMID: 26874565     DOI: 10.1016/j.jelectrocard.2016.01.005

Source DB:  PubMed          Journal:  J Electrocardiol        ISSN: 0022-0736            Impact factor:   1.438


  1 in total

1.  Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study.

Authors:  Rafael Caire de Oliveira Dos Santos; Alessandra Carvalho Goulart; Alan Loureiro Xavier Kisukuri; Rodrigo Martins Brandão; Debora Sitnik; Henrique Lane Staniak; Marcio Sommer Bittencourt; Paulo Andrade Lotufo; Isabela Martins Bensenor; Itamar de Souza Santos
Journal:  Arq Bras Cardiol       Date:  2016-10       Impact factor: 2.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.